Trial Profile
Phase I Trial Of Cisplatin And KML-001 In Advanced Non-Small Cell Lung Cancer and Other Platinum Responsive Malignancies.
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 18 Mar 2020
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary) ; Sodium metaarsenite (Primary)
- Indications Cancer; Germ cell and embryonal neoplasms; Germ cell cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Urogenital cancer
- Focus Adverse reactions; Pharmacogenomic
- 13 Mar 2020 Status changed from completed to discontinued.
- 01 Nov 2016 Status changed from recruiting to completed as per results published in the Cancer Chemotherapy and Pharmacology.
- 01 Oct 2012 Planned End Date changed from 1 Apr 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.